Pulmonary administration of a water-soluble curcumin complex reduces severity of acute lung injury

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 3, 2012, Pages 280-287

  Suresh, Madathilparambil V ^a   Wagner, Matthew C ^c   Rosania, Gus R ^b   Stringer, Kathleen A ^b   Min, Kyoung Ah ^b   Risler, Linda ^d   Shen, Danny D ^d   Georges, George E ^d   Reddy, Aravind T ^c   Parkkinen, Jaakko ^d,e   Reddy, Raju C ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Calu 3; Cyclodextrin; LPS; Oxidative stress; TEER; Turmeric

Indexed keywords

CURCUMIN; GAMMA CYCLODEXTRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MONOLAYER CULTURE; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; RESPIRATORY EPITHELIUM; SOLUBILIZATION;

ACUTE LUNG INJURY; ANIMALS; CELL LINE; CURCUMIN; DRUG ADMINISTRATION ROUTES; MALE; MICE; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

CURCUMA LONGA; MURINAE;

EID: 84865831359     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0175OC     Document Type: Article

References (44)

1. Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med 2010;107: 252-258.
2. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008;295:L379-L399.
3. Ward PA. Oxidative stress: acute and progressive lung injury. Ann N Y Acad Sci 2010;1203:53-59.
4. Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs 2010;70:1255-1282.
5. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-2087.
6. Chen Y-R, Tan T-H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998;17:173-178. (Pubitemid 28371890)
7. Gaedeke J, Noble NA, BorderWA. Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int 2004;66:112-120. (Pubitemid 38870087)
8. Hu M, Du Q, Vancurova I, Lin X, Miller EJ, Simms HH, Wang P. Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen- activated protein kinase pathway. Crit Care Med 2005;33:2571-2578. (Pubitemid 41682110)
9. Zhou Y, Zheng S, Lin J, Zhang QJ, Chen A. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARγ in rat activated hepatic stellate cell in vitro. Lab Invest 2007;87:488-498. (Pubitemid 46633122)
10. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90:1011-1015. (Pubitemid 38499692)
11. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-153.
12. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-1968. (Pubitemid 41557681)
13. Smith MR, Gangireddy SR, Narala VR, Hogaboam CM, Standiford TJ, Christensen PJ, Kondapi AK, Reddy RC. Curcumin inhibits fibrosisrelated effects in IPF fibroblasts and in mice following bleomycininduced lung injury. Am J Physiol Lung Cell Mol Physiol 2010;298: L616-L625.
14. Yadav VR, Prasad S, Kannappan R, Ravindran J, Chaturvedi MM, Vaahtera L, Parkkinen J, Aggarwal BB. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 2010;80:1021-1032.
15. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007;5:3.
16. Schiborr C, Eckert GP, Rimbach G, Frank J. A validated method for the quantification of curcumin in plasma and brain tissue by fast narrowbore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 2010;397:1917-1925.
17. Mohorko N, Repovs G, Popovic M, Kovacs GG, Bresjanac M. Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol 2010;69:405-414.
18. Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 2000;208:1-11.
19. Lacombe O, Woodley J, Solleux C, Delbos JM, Boursier-Neyret C, Houin G. Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci 2004;23:385-391. (Pubitemid 39573390)
20. Wang Y, Phelan SA, Manevich Y, Feinstein SI, Fisher AB. Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia. Am J Respir Cell Mol Biol 2006;34:481-486.
21. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids: XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002;244:127-135. (Pubitemid 35245453)
22. Kumar A, Ahuja A, Ali J, Baboota S. Conundrum and therapeutic potential of curcumin in drug delivery. Crit Rev Ther Drug Carrier Syst 2010;27:279-312.
23. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-356. (Pubitemid 28234275)
24. Southam DS, Dolovich M, O'Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 2002;282:L833- L839.
25. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 2009;6:192-199.
26. Forbes B. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today 2000;3:18-27. (Pubitemid 30066491)
27. Mathia NR, Timoszyk J, Stetsko PI, Megill JR, Smith RL, Wall DA. Permeability characteristics of Calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target 2002;10:31-40. (Pubitemid 34223847)
28. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 2003;92:1216-1233. (Pubitemid 36676468)
29. Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer UF, Hanes J, Lehr CM. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med 2002;15:131-139. (Pubitemid 34827526)
30. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045-2076. (Pubitemid 128633447)
31. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-351. (Pubitemid 41130887)
32. Tewes F, Brillault J, Couet W, Olivier JC. Formulation of rifampicin- cyclodextrin complexes for lung nebulization. J Control Release 2008; 129:93-99.
33. Matilainen L, Toropainen T, Vihola H, Hirvonen J, Jarvinen T, Jarho P, Jarvinen K. In vitro toxicity and permeation of cyclodextrins in Calu- 3 cells. J Control Release 2008;126:10-16.
34. Salem LB, Bosquillon C, Dailey LA, Delattre L, Martin GP, Evrard B, Forbes B. Sparing methylation of beta-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. J Control Release 2009;136:110-116.
35. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001;90:690-701. (Pubitemid 32530445)
36. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-1035. (Pubitemid 39642365)
37. Nagarsenker MS, Meshram RN, Ramprakash G. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of invitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J Pharm Pharmacol 2000;52:949- 956.
38. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991;88:5292-5296.
39. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK, Kim KW. Curcumin inhibits hypoxia-induced angiogenesis via downregulation of HIF-1. Oncol Rep 2006;15:1557-1562.
40. Lian Q, Li X, Shang Y, Yao S, Ma L, Jin S. Protective effect of curcumin on endotoxin-induced acute lung injury in rats. J Huazhong Univ Sci Technolog Med Sci 2006;26:678-681.
41. Olszanecki R, Gebska A, Korbut R. The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin. Basic Clin Pharmacol Toxicol 2007;101:411-415. (Pubitemid 350135353)
42. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-1684.
43. ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS network. JAMA 2000;283:1995-2002.
44. ARDS Clinical Trials Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002;30:1-6.